Human methylome studies SRP450395 Track Settings
 
Epigenetic therapy targets the 3D epigenome in endocrine-resistant breast cancer [WGBS] [Breast Cancer PDX Model Gar15-13, Breast Cancer PDX Model HCI005]

Track collection: Human methylome studies

+  All tracks in this collection (438)

Maximum display mode:       Reset to defaults   
Select views (Help):
AMR       CpG reads ▾       PMD       CpG methylation ▾      
Select subtracks by views and experiment:
 All views AMR  CpG reads  PMD  CpG methylation 
experiment
SRX21082210 
SRX21082211 
SRX21082212 
SRX21082213 
SRX21082214 
SRX21082215 
SRX21082216 
SRX21082217 
List subtracks: only selected/visible    all    ()
  experiment↓1 views↓2   Track Name↓3  
hide
 Configure
 SRX21082210  CpG methylation  Breast Cancer PDX Model Gar15-13 / SRX21082210 (CpG methylation)   Data format 
hide
 Configure
 SRX21082211  CpG methylation  Breast Cancer PDX Model Gar15-13 / SRX21082211 (CpG methylation)   Data format 
hide
 Configure
 SRX21082212  CpG methylation  Breast Cancer PDX Model Gar15-13 / SRX21082212 (CpG methylation)   Data format 
hide
 Configure
 SRX21082213  CpG methylation  Breast Cancer PDX Model Gar15-13 / SRX21082213 (CpG methylation)   Data format 
hide
 Configure
 SRX21082214  CpG methylation  Breast Cancer PDX Model HCI005 / SRX21082214 (CpG methylation)   Data format 
hide
 Configure
 SRX21082215  CpG methylation  Breast Cancer PDX Model HCI005 / SRX21082215 (CpG methylation)   Data format 
hide
 Configure
 SRX21082216  CpG methylation  Breast Cancer PDX Model HCI005 / SRX21082216 (CpG methylation)   Data format 
hide
 Configure
 SRX21082217  CpG methylation  Breast Cancer PDX Model HCI005 / SRX21082217 (CpG methylation)   Data format 
    
Assembly: Human Dec. 2013 (GRCh38/hg38)

Study title: Epigenetic therapy targets the 3D epigenome in endocrine-resistant breast cancer [WGBS]
SRA: SRP450395
GEO: not found
Pubmed: not found

Experiment Label Methylation Coverage HMRs HMR size AMRs AMR size PMDs PMD size Conversion Title
SRX21082210 Breast Cancer PDX Model Gar15-13 0.574 15.0 77033 9717.0 2154 1063.5 3233 349520.2 0.987 GSM7648672: Gar15-13 Vehicle 1; Homo sapiens; Bisulfite-Seq
SRX21082211 Breast Cancer PDX Model Gar15-13 0.574 12.9 71896 10363.9 1840 1073.9 3189 355123.7 0.986 GSM7648673: Gar15-13 Vehicle 2; Homo sapiens; Bisulfite-Seq
SRX21082212 Breast Cancer PDX Model Gar15-13 0.458 17.0 80898 10377.3 1404 1056.5 3553 298335.1 0.986 GSM7648674: Gar15-13 Decitabine 1; Homo sapiens; Bisulfite-Seq
SRX21082213 Breast Cancer PDX Model Gar15-13 0.461 12.7 67378 11313.1 1224 1048.3 3274 320667.1 0.987 GSM7648675: Gar15-13 Decitabine 2; Homo sapiens; Bisulfite-Seq
SRX21082214 Breast Cancer PDX Model HCI005 0.573 12.4 87391 7157.2 5755 1211.0 3955 200405.5 0.984 GSM7648676: HCI-005 Vehicle 1; Homo sapiens; Bisulfite-Seq
SRX21082215 Breast Cancer PDX Model HCI005 0.566 11.6 83439 7556.4 5652 1196.3 2750 301568.5 0.986 GSM7648677: HCI-005 Vehicle 2; Homo sapiens; Bisulfite-Seq
SRX21082216 Breast Cancer PDX Model HCI005 0.536 12.3 84267 7395.4 5129 1170.7 4007 198553.1 0.986 GSM7648678: HCI-005 Decitabine 1; Homo sapiens; Bisulfite-Seq
SRX21082217 Breast Cancer PDX Model HCI005 0.533 13.0 86724 7368.9 5901 1186.9 4052 199606.5 0.987 GSM7648679: HCI-005 Decitabine 2; Homo sapiens; Bisulfite-Seq

Methods

All analysis was done using a bisulfite sequnecing data analysis pipeline DNMTools developed in the Smith lab at USC.

Mapping reads from bisulfite sequencing: Bisulfite treated reads are mapped to the genomes with the abismal program. Input reads are filtered by their quality, and adapter sequences in the 3' end of reads are trimmed. This is done with cutadapt. Uniquely mapped reads with mismatches/indels below given threshold are retained. For pair-end reads, if the two mates overlap, the overlapping part of the mate with lower quality is discarded. After mapping, we use the format command in dnmtools to merge mates for paired-end reads. We use the dnmtools uniq command to randomly select one from multiple reads mapped exactly to the same location. Without random oligos as UMIs, this is our best indication of PCR duplicates.

Estimating methylation levels: After reads are mapped and filtered, the dnmtools counts command is used to obtain read coverage and estimate methylation levels at individual cytosine sites. We count the number of methylated reads (those containing a C) and the number of unmethylated reads (those containing a T) at each nucleotide in a mapped read that corresponds to a cytosine in the reference genome. The methylation level of that cytosine is estimated as the ratio of methylated to total reads covering that cytosine. For cytosines in the symmetric CpG sequence context, reads from the both strands are collapsed to give a single estimate. Very rarely do the levels differ between strands (typically only if there has been a substitution, as in a somatic mutation), and this approach gives a better estimate.

Bisulfite conversion rate: The bisulfite conversion rate for an experiment is estimated with the dnmtools bsrate command, which computes the fraction of successfully converted nucleotides in reads (those read out as Ts) among all nucleotides in the reads mapped that map over cytosines in the reference genome. This is done either using a spike-in (e.g., lambda), the mitochondrial DNA, or the nuclear genome. In the latter case, only non-CpG sites are used. While this latter approach can be impacted by non-CpG cytosine methylation, in practice it never amounts to much.

Identifying hypomethylated regions (HMRs): In most mammalian cells, the majority of the genome has high methylation, and regions of low methylation are typically the interesting features. (This seems to be true for essentially all healthy differentiated cell types, but not cells of very early embryogenesis, various germ cells and precursors, and placental lineage cells.) These are valleys of low methylation are called hypomethylated regions (HMR) for historical reasons. To identify the HMRs, we use the dnmtools hmr command, which uses a statistical model that accounts for both the methylation level fluctations and the varying amounts of data available at each CpG site.

Partially methylated domains: Partially methylated domains are large genomic regions showing partial methylation observed in immortalized cell lines and cancerous cells. The pmd program is used to identify PMDs.

Allele-specific methylation: Allele-Specific methylated regions refers to regions where the parental allele is differentially methylated compared to the maternal allele. The program allelic is used to compute allele-specific methylation score can be computed for each CpG site by testing the linkage between methylation status of adjacent reads, and the program amrfinder is used to identify regions with allele-specific methylation.

For more detailed description of the methods of each step, please refer to the DNMTools documentation.